Non-Small Cell Lung Cancer Therapeutics Market Expected to Reach US$ 15.1 Bn in 2023: Transparency Market Research

02 Dec, 2015, 10:30 ET from Transparency Market Research

ALBANY, New York, December 2, 2015 /PRNewswire/ --

Transparency Market Research has published a new market report titled, "Non-Small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023." According to the report, the global non small cell lung cancer market was valued at US$ 4.9 Bn in 2014 and is anticipated to expand at a CAGR of 12.1% from 2015 to 2023 to reach US$ 15.1 Bn in 2023.

Browse the full Non Small Cell Lung Cancer Therapeutics Market: (By Drug Class: Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023 report at http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

The report provides detailed analysis of current and emerging drugs for non small cell lung cancer (NSCLC), segmenting them based on type of drug class. Drugs have been analyzed by segments such as angiogenesis inhibitor, EGFR inhibitor, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitor. Angiogenesis inhibitor was the largest segment of the global non-small cell lung cancer market in 2014. High demand for Avastin in major geographies such as Europe and the U.S. is likely to propel the segment during the forecast period. The angiogenesis inhibitor segment was valued at US$ 1,627.1 Mn in 2014 and is likely to account for US$ 2,020.4 Mn by 2023, expanding at a CAGR of 1.8% from 2015 to 2023.

Get Sample Report Copy of Non-Small Cell Lung Cancer Therapeutics Market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

The folate antimetabolites segment is projected to be the second highest segment of the global NSCLC therapeutics market. The EGFR inhibitor and microtubule stabilizer segments held the third and fourth largest shares of the market in terms of revenue in 2014. However, entry of new targeted therapies with more surveillance rate could restrain market growth. PD-1/PD-L1 inhibitor is likely to the fastest growing segment during the forecast period, due to affectivity of the treatment as clinical data showed double survival rate. The non-small cell lung cancer therapeutics market is anticipated to be driven by increase in incidence and diagnosis rate, government initiatives leading to rapid approval of the treatment, and development of targeted therapies

Browse Press Release of Non-Small Cell Lung Cancer Therapeutics Market: http://www.transparencymarketresearch.com/pressrelease/non-small-cell-lung-cancer-market.htm

The report offers a detailed analysis of factors responsible for market growth and outlines a possible growth trajectory for other segments. The report is thus compiled with the primary objective of updating the stakeholders with the market dynamics, which are graphically illustrated.

AstraZeneca plc, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Novartis AG, Eli Lilly and Company, Pfizer, Inc., Genentech, Inc. (a Roche company), and Sun Pharmaceutical Industries Ltd. are the major companies operating in the global non small cell lung cancer therapeutics market. Genentech, a Roche company, was identified as the leading player in the global non-small cell lung cancer therapeutics market in 2014, accounting for a revenue share of more than 36%, followed by Eli Lilly and Company.

Other Reports by Transparency Market Research: 


The global non-small cell lung cancer therapeutics market has been segmented as follows:

Global Non-Small Cell Lung Cancer Therapeutics Market, by Drug Class, 2013-2023 (US$ Mn) 

  • Overview
  • Angiogenesis Inhibitor
    • Avastin (bevacizumab)
    • Cyramza (Ramucirumab)
  • Epidermal Growth Factor Receptor Blocker
    • Tarceva (erlotinib)
    • Gilotrif (afatinib)
    • Iressa (gefitinib)
  • Kinase Inhibitor
    • Xalkori (crizotinib)
    • Zykadia (ceritinib)
  • Microtubule Stabilizer
    • Abraxane (paclitaxel protein bound)
    • Docetaxel
  • Folate Antimetabolites
    • Alimta (pemetrexed)
  • PD-1/ PD-L1 Inhibitor
    • Opdivo (nivolumab)
    • Keytruda (pembrolizumab)

Pipeline Analysis: Global Non-Small Cell Lung Cancer Therapeutics Market 

  • Overview
  • Late Stage (Phase III) Forecast for Phase III Drugs Post Expected Launch till 2023 (US$ Mn)
    • Avelumab - Pfizer, Inc.
    • MPDL3280A - Roche
    • MEDI4736 - AstraZeneca
    • Abemaciclib - Eli Lilly and Company
    • Others
  • Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)

Global Non-Small Cell Lung Cancer Therapeutics Market, by Geography, 2013-2023 (US$ Mn) 

  • Overview
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Rest of the World

About Us:  

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact:

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Blog: http://www.tmrblog.com/


SOURCE Transparency Market Research